Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEPADINA AND SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tepadin A (thiotepa) is an alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death. It is cell cycle phase-nonspecific.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Treatment of adenocarcinoma of the breast,Treatment of adenocarcinoma of the ovary,Palliative treatment of superficial papillary carcinoma of the urinary bladder,Conditioning regimen prior to allogeneic or autologous hematopoietic progenitor cell transplantation (off-label)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
6.25 mg/m2 (based on ideal body weight) intravenously over 2 hours every 6 hours for 16 doses (total dose 100 mg/m2) as part of conditioning regimen prior to hematopoietic stem cell transplantation.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life: 1.5–3.5 hours; clinically, the short half-life allows high-intensity dosing with stem cell support
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Primarily metabolized by cytochrome P450 enzymes, including CYP2B6 and CYP3A4, via oxidative desulfuration to active metabolites (e.g., tepa). Also undergoes glutathione conjugation.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Primarily renal; approximately 60-70% of the dose is excreted unchanged in urine within 24 hours; minor fecal elimination (<10%)
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Minimal (<10%); primarily albumin
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
0.3–0.5 L/kg; indicates limited extravascular distribution
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Oral: approximately 75% (variable, 30-100%); intravenous: 100%
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No specific dose adjustments are provided for renal impairment. Use with caution in patients with renal impairment due to potential for nephrotoxicity from the drug or its metabolites; monitor renal function closely.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific dose adjustments are provided for hepatic impairment based on Child-Pugh score. Use with caution in patients with hepatic impairment; monitor liver function tests closely.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Children and adolescents: Same dose as adults (6.25 mg/m2 intravenously over 2 hours every 6 hours for 16 doses), based on ideal body weight. Safety and efficacy in neonates and infants have not been established.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
No specific dose adjustments recommended for elderly patients. Use with caution due to higher likelihood of decreased renal and hepatic function, and monitor for increased toxicity.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
WARNING: THIOTEPA IS HIGHLY TOXIC TO BONE MARROW. SEVERE MYELOSUPPRESSION, INCLUDING DEATH, MAY OCCUR. THIOTEPA IS CARCINOGENIC AND MUTAGENIC. IT SHOULD BE ADMINISTERED ONLY BY PHYSICIANS EXPERIENCED IN CANCER CHEMOTHERAPY.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Bone marrow suppression: Monitor blood counts frequently; dose adjustments may be necessary.,Carcinogenicity: Long-term use increases risk of secondary malignancies (e.g., myelodysplastic syndrome, acute leukemia).,Mutagenicity: Can cause chromosomal damage; use contraception during therapy.,Renal and hepatic impairment: Dose adjustment may be needed.,Hemorrhagic cystitis: Adequate hydration and frequent voiding recommended; monitor for hematuria.,Embryo-fetal toxicity: Can cause fetal harm; avoid pregnancy.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to thiotepa or any component of the formulation,Severe bone marrow depression (e.g., leukopenia, thrombocytopenia)
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No specific food interactions. Maintain adequate hydration. Avoid grapefruit juice due to potential CYP3A4 interaction. Advise small, frequent meals to manage nausea.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
TEPADINA is a known teratogen in animals and is presumed to cause fetal harm when administered to pregnant women. Based on its mechanism of action as an alkylating agent, there is a high risk of teratogenicity, including congenital malformations and fetal demise, particularly during the first trimester. In the second and third trimesters, exposure may lead to fetal growth restriction, myelosuppression, or long-term developmental effects.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
There are no data on the presence of TEPADINA in human milk, its effects on the breastfed infant, or its effects on milk production. Due to the potential for serious adverse reactions in nursing infants, including myelosuppression and carcinogenicity, breastfeeding should be discontinued during treatment and for at least 2 weeks after the last dose.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No specific pharmacokinetic data are available for dosing adjustments in pregnancy. However, due to physiological changes in pregnancy (e.g., increased plasma volume, altered hepatic metabolism), careful monitoring for toxicity and efficacy is warranted. No standard dose adjustment is recommended; dosing should be based on therapeutic drug monitoring if available and clinical response.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
TEPADINA AND SODIUM CHLORIDE is used as a conditioning agent prior to hematopoietic stem cell transplantation (HSCT). Administer via intravenous infusion over 1-2 hours. Monitor for infusion reactions (bronchospasm, urticaria) and have resuscitation equipment available. Pre-medicate with anticonvulsants (e.g., phenytoin) to prevent seizure due to CNS toxicity. Observe for hepatotoxicity, especially veno-occlusive disease (VOD), and consider defibrotide prophylaxis. Adjust dose for renal impairment (Cr Cl < 60 m L/min). Use with caution in patients with pre-existing hepatic dysfunction.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This medication is used to prepare your body for a stem cell transplant.,You will receive this drug intravenously (through a vein) in the hospital.,Common side effects include nausea, vomiting, diarrhea, and mouth sores.,You may experience temporary hair loss and skin rash.,Report any signs of infection (fever, chills), bleeding, or unusual bruising immediately.,Avoid driving or operating machinery if you feel dizzy or sleepy.,Do not receive live vaccines during treatment.,Use effective contraception during and for at least 6 months after treatment.,Drink plenty of fluids unless advised otherwise.,Inform your doctor if you have liver or kidney disease.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEPADINA AND SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
TEPADINA AND SODIUM CHLORIDE is a Electrolyte that works by Tepadin A (thiotepa) is an alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death. It is cell cycle phase-nonspecific.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEPADINA AND SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEPADINA AND SODIUM CHLORIDE is: 6.25 mg/m2 (based on ideal body weight) intravenously over 2 hours every 6 hours for 16 doses (total dose 100 mg/m2) as part of conditioning regimen prior to hematopoietic stem cell transplantation.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining TEPADINA AND SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. TEPADINA AND SODIUM CHLORIDE is classified as Category A/B. TEPADINA is a known teratogen in animals and is presumed to cause fetal harm when administered to pregnant women. Based on its mechanism of action as an alkylating agent, there is . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.